Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031Awa Sarr, Paul A. Reynolds|Scientific Reports|2019Cited by 17
Abstract 1855: NUC-1031 overcomes resistance associated with gemcitabine in cancer patientsJennifer Bré, David J. Harrison, Peter Mullen et al.|Cancer Research|2018Cited by 2